Hospital-at-Home Plus Fecal Transplant Saves Money for Elderly C. diff Patients
Danish study shows combining home care with fecal microbiota transplantation reduces costs by €2,556 per patient while improving outcomes.
Summary
A Danish randomized trial of 217 patients aged 70+ with C. difficile infection found that combining hospital-at-home care with fecal microbiota transplantation (FMT) was cost-effective compared to standard treatment. The intervention saved an average of €2,556 per patient over 90 days while reducing hospital stays by 6 days and improving infection resolution rates. Despite higher resource use for home visits and assessments, the approach was economically dominant due to fewer hospitalizations. This suggests a promising model for treating elderly patients with this serious gut infection that affects 24-36% mortality rates in this age group.
Detailed Summary
Clostridioides difficile infection (CDI) poses a major threat to elderly patients, with 90-day mortality rates of 24-36% in those experiencing their first infection. The condition costs Europe an estimated €3 billion annually, with prolonged hospital stays driving much of the expense. While fecal microbiota transplantation (FMT) has proven clinically effective for recurrent CDI, its integration with alternative care models remains underexplored.
Researchers from Aarhus University Hospital conducted a cost-utility analysis using data from the CLODIfrail randomized trial, which enrolled 217 patients aged 70 and older with CDI. Half received standard hospital care, while the other half received a comprehensive intervention combining hospital-at-home (HaH) care with FMT. The intervention included early geriatric assessment, home visits by specialist nurses and geriatricians, FMT treatment (primarily via capsules), and 8-week follow-up care.
The economic analysis revealed striking results. The intervention was "dominant" - meaning it both saved money and improved health outcomes. Patients in the intervention group experienced average cost savings of €2,556 ($2,764) over 90 days, primarily due to 6 fewer hospital admission days per patient. Despite higher resource use for home visits and assessments, the intervention group had better clinical outcomes, including higher rates of CDI resolution and fewer readmissions.
The intervention group received FMT at much higher rates (102 patients vs. 33 in the control group), contributing to better infection control. Quality-adjusted life years (QALYs) showed a modest improvement of 0.004 per patient. The results remained robust across multiple sensitivity analyses, including different cost perspectives and variations in hospital admission pricing.
These findings suggest that reimagining care delivery for elderly CDI patients through home-based comprehensive care combined with proven therapies like FMT could simultaneously improve outcomes and reduce healthcare costs - a rare win-win in healthcare economics.
Key Findings
- Hospital-at-home plus FMT saved €2,556 per elderly CDI patient over 90 days
- Intervention reduced hospital stays by average of 6 days per patient
- Higher FMT usage (102 vs 33 patients) improved infection resolution rates
- Cost savings remained robust across different economic analysis perspectives
- Approach was economically dominant despite higher home care resource use
Methodology
Randomized controlled trial of 217 patients aged ≥70 with CDI, comparing hospital-at-home care plus FMT versus standard treatment over 90 days. Cost-utility analysis used healthcare sector perspective with quality-adjusted life years as primary outcome measure.
Study Limitations
Study limited to Danish healthcare system with 90-day follow-up period. Missing baseline quality-of-life data required imputation methods. Results may not generalize to healthcare systems with different cost structures or home care capabilities.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.